Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Semel Institute for Neuroscience and Human Behavior awarded $14.9M to establish IPCN facility

The Semel Institute for Neuroscience and Human Behavior at UCLA has been awarded $14.9 million in American Recovery and Reinvestment Act funds to establish a center dedicated to interdisciplinary research on the role of genetic and environmental factors in neuropsychiatric and behavioral disorders.

7 Apr 2010

Defective protein responsible for SCA5 disease cuts synaptic terminals and snarls traffic inside neurons

The neurodegenerative disease spinocerebellar ataxia type 5 (SCA5) damages nerve cells in two ways. University of Minnesota researchers now report that the defective protein responsible for the disease cuts the number of synaptic terminals and snarls traffic inside neurons.

7 Apr 2010

New study shows utility of Chronix Biomedical's serum DNA tests in MS

Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis. Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells.

6 Apr 2010

ExonHit Therapeutics obtains "Innovative Company" accreditation

ExonHit Therapeutics today announced that it has obtained the "Innovative Company" accreditation from OSEO (the French state innovation agency), in recognition of the company's cutting-edge innovations in its target sectors.

6 Apr 2010

Scientists develop low-cost behavioral assessment to detect progression of MCI

Your brain's capacity for information is a reliable predictor of Alzheimer's disease and can be cheaply and easily tested, according to scientists.

6 Apr 2010

Menstrual stem cells may help in treatment of stroke and central nervous system disorders

Cryo-Cell International, Inc. today announced results of a study published this month in the cover article of Stem Cells and Development showing that stem cells found in menstrual blood may one day be a potential source for stem cell therapies in stroke and other central nervous system disorders.

5 Apr 2010

Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).

5 Apr 2010

Some therapies being investigated for Alzheimer's disease may cause cell death: UCSD

Some current therapies being investigated for Alzheimer's disease may cause further neural degeneration and cell death, according to a breakthrough discovery by UC San Diego researchers. By combining three dimensional computer simulations with high resolution atomic force microscopy membrane protein and cell imaging, electrical recording and various cellular assays, UCSD nano-biophysicist Ratnesh Lal and his colleagues investigated the structure and function of truncated peptides, known as nonamyloidgenic peptides, formed by some Alzheimer's drug candidates.

5 Apr 2010

Clinical utility and pharmacological action of MN-166 in treatment of MS

MediciNova, Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today reported that this week's issue of Neurology includes two articles related to the potential clinical utility and unique pharmacological action of MN-166 in treating multiple sclerosis (MS).

3 Apr 2010

New production method yields hundredsfold more ubiquitylated proteins critical for cancer research

Scientists at the University of Delaware have developed a new method for producing proteins critical to research on cancer, Alzheimer's, and other diseases.

3 Apr 2010

Molecular mechanism behind mutation in calcium channel protein linked with night blindness

Congenital stationary night blindness, an inherited condition that affects one's ability to see in the dark, is caused by a mutation in a calcium channel protein that shuttles calcium into and out of cells. Now, researchers at the Johns Hopkins University School of Medicine have teased apart the molecular mechanism behind this mutation, uncovering a more general principle of how cells control calcium levels.

2 Apr 2010

Mouse study indicates rapamycin drug prevents Alzheimer's disease, extends lifespan

If research results continue to be repeated and are turned into clinical trials, a drug already approved for some uses could be marshaled - sooner than we expect - to prevent Alzheimer's disease in humans and improve health to the end of life.

2 Apr 2010

BELLUS Health initiates Phase I clinical study for NRM8499

BELLUS Health Inc. announced today that, on March 30, 2010, the Company initiated a Phase I clinical study for NRM8499, a prodrug of tramiprosate. NRM8499 is intended for the treatment of Alzheimer's disease.

1 Apr 2010

Metabolon awarded U.S. patents for metabolomics methods

Metabolon, Inc., the leader in global metabolism through biomarker discovery and analysis, announced today the grant of US Patent 7,682,783 and US Patent 7,682,784 entitled "Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics". The USPTO awarded the patents to Metabolon on March 23, 2010. The issued claims in the new patents are for uses of metabolomics to identify diagnostic biomarkers for depression and schizophrenia by profiling classes of metabolites in a sample.

1 Apr 2010

Researchers develop experimental protocol to detect age-related memory disorders

By studying the aging of memory in the mouse, researchers in the Laboratoire Neurobiologie des Processus Adaptatifs have developed an experimental protocol that can detect age-related memory deficits at an early stage. They have shown that even at 10 months, which corresponds to a third of their life expectancy, some mice present with age-related memory disorders.

1 Apr 2010

Neurologist develops SAGE tool to diagnose memory disorders

A self-administered test to screen for early dementia could help speed the diagnosis and subsequent treatment of memory disorders, including Alzheimer's disease. It could also provide health care providers and caregivers an earlier indication of life-changing events that could lie ahead.

1 Apr 2010

ADDF grants Signum Biosciences $270,000 for evaluating PP2A-modulatory compounds as AD therapeutics

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it is providing a grant of $270,000 to Signum Biosciences, Inc. (Princeton, NJ) to evaluate small-molecule, orally delivered Protein Phosphatase 2a (PP2A)-modulatory compounds as disease-modifying therapeutics for Alzheimer's disease.

1 Apr 2010

Cell study may yield new treatment strategies for debilitating diseases

A Los Alamos National Laboratory toxicologist and a multidisciplinary team of researchers have documented potential cellular damage from "fullerenes"-soccer-ball-shaped, cage-like molecules composed of 60 carbon atoms. The team also noted that this particular type of damage might hold hope for treatment of Parkinson's disease, Alzheimer's disease, or even cancer.

1 Apr 2010

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.

31 Mar 2010

AFFiRiS AG develops PD01 vaccine for Parkinson's disease

Today AFFiRiS AG announced an important step forward in the development of its vaccine for Parkinson's disease. The vaccine, known as PD01, has undergone numerous preclinical tests which have confirmed its principle of action ("Proof of Concept").

31 Mar 2010

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Semel Institute for Neuroscience and Human Behavior awarded $14.9M to establish IPCN facility

Defective protein responsible for SCA5 disease cuts synaptic terminals and snarls traffic inside neurons

New study shows utility of Chronix Biomedical's serum DNA tests in MS

ExonHit Therapeutics obtains "Innovative Company" accreditation

Scientists develop low-cost behavioral assessment to detect progression of MCI

Menstrual stem cells may help in treatment of stroke and central nervous system disorders

Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

Some therapies being investigated for Alzheimer's disease may cause cell death: UCSD

Clinical utility and pharmacological action of MN-166 in treatment of MS

New production method yields hundredsfold more ubiquitylated proteins critical for cancer research

Molecular mechanism behind mutation in calcium channel protein linked with night blindness

Mouse study indicates rapamycin drug prevents Alzheimer's disease, extends lifespan

BELLUS Health initiates Phase I clinical study for NRM8499

Metabolon awarded U.S. patents for metabolomics methods

Researchers develop experimental protocol to detect age-related memory disorders

Neurologist develops SAGE tool to diagnose memory disorders

ADDF grants Signum Biosciences $270,000 for evaluating PP2A-modulatory compounds as AD therapeutics

Cell study may yield new treatment strategies for debilitating diseases

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

AFFiRiS AG develops PD01 vaccine for Parkinson's disease

Innovation in neuroscience drug discovery - eBook eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Innovation in neuroscience drug discovery - eBook eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in